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AbstrACt
Introduction Understanding the impact of cancer and 
its treatment on people’s everyday lives will help prepare 
people for what to expect, enable health professionals 
to predict likely recovery trajectories and shape care 
management according to needs. HORIZONS will recruit 
people awaiting treatment and follow them up at regular 
intervals to assess recovery of health and well-being.
research questions What impact does cancer 
diagnosis and treatment have on people’s lives in 
the short, medium and long term? What are people’s 
health and well-being outcomes, experiences and self-
management activities over time across different cancer 
types and what influences these? How do people connect 
with and relate to others in mobilising resources that 
enable them to self-manage the consequences of cancer 
and treatment?
Methods and analysis HORIZONS is a multicentre, 
prospective cohort study exploring recovery of health and 
well-being in 3000 people diagnosed with breast cancer 
(<50 years), non-Hodgkin's lymphoma or gynaecological 
cancer. Recruitment will take place across National 
Health Service (NHS) sites in the UK between September 
2016 and March 2019, before primary treatment starts. 
Participants will be identified through clinical teams and 
invited to complete questionnaires including assessments 
of quality of life, symptoms and functioning (Quality of 
Life in Adult Cancer Survivors; European Organisation for 
Research and Treatment Consortium Core quality of life 
questionnaire, EORTC-QLQ-C30), health status (EuroQol-5 
dimensions, EQ-5D), self-efficacy, social support, social 
networks and lifestyle. Clinical data will also be collected. 
Descriptive statistics will characterise outcomes. Changes 
over time will be investigated. Factors that may influence 
recovery and self-management will be included in 
regression models to determine which influence health 
and well-being and self-management.
Ethics and dissemination Ethics and Health Research 
Authority approvals granted (IRAS Project ID: 202342, REC 
reference number 16/NW/0425). Adopted onto the National 
Institute for Health Research Clinical Research Network 
portfolio. We will engage with our Scientific Advisory 
Board, Tumour Specific Expert Panels, User Reference 
Group, Macmillan and the University of Southampton to 
ensure maximum publicity and benefit.
IntroduCtIon
Around 13 million people worldwide are 
diagnosed with cancer every year. This figure 
is expected to triple by 2050. The number of 
people living with and beyond cancer in the 
UK is expected to reach four million by 2030.1 
Healthcare systems need to adapt to manage 
this demand and better meet the needs of 
this growing population. Global initiatives 
are exploring ways to improve care for cancer 
survivors and calling for high-quality inter-
disciplinary research to provide evidence to 
inform the most effective ways to support 
survivors to improve health and well-being.2 
Benefits can be experienced following a 
cancer diagnosis; however, many people face 
challenges that can have a major impact on all 
aspects of daily life.3 The need for support in 
managing this has been highlighted.4 People 
can be unprepared for the impact on their 
lives, may feel vulnerable, experience loss of 
confidence, struggle to manage and access 
care and support.3 5–7 This in turn may have 
implications for recovery, self-management 
and timely access to appropriate services. 
strengths and limitations of this study
 ► A combination of patient-reported outcomes and 
clinical data from medical notes.
 ► Completion of patient-reported outcome measures 
prior to treatment commencing.
 ► Total sample identified and approached wherever 
possible in multiple sites across the UK.
 ► Collection of data on a range of theoretically in-
formed variables to understand the wider impact of 
cancer and treatment on everyday lives.
 ► Not possible to collect baseline measures of health 
and well-being prior to cancer diagnosis or recruit 
a comparator cohort, however, specific outcome 
measures are included to allow for comparisons to 
existing UK longitudinal population studies.
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In these respects, the current healthcare system is not 
adequately meeting the needs of people after cancer 
treatment.8
In order to address future needs appropriately it is 
necessary to understand how people live with and manage 
the consequences of cancer and its treatment so that 
they can be supported optimally, consider their ability 
to manage this and the implications for their personal 
networks in supporting them. Increasingly, clinical trials 
collect quality of life (QoL) data. However, clinical trials 
are applicable to a minority of patients and have high 
dropout rates9 and QoL assessments alone do not give 
a full picture of the impact of cancer and treatment on 
everyday life or how people manage. A number of initia-
tives have collected regional or national patient-reported 
psychosocial outcomes including QoL data to investigate 
the wider aspects of recovery following a cancer diagnosis 
and treatment. These include cross-sectional studies 
providing a snapshot of recovery in time,10–12 longitu-
dinal studies monitoring changes over time8 13 and trials 
of psychosocial interventions.14 None of these, however, 
combine a longitudinal design with measurement of 
outcomes before and after the start of treatment which 
would allow better understanding of the consequences of 
cancer treatment on recovery.
HORIZONS will improve our understanding of 
recovery following curative intent treatment for cancer, 
providing in-depth and wide-ranging evidence. HORI-
ZONS uses a prospective, cohort approach to gather 
patient reported and clinical data, involving represen-
tative groups of people recently diagnosed with cancer 
to reveal how the consequences of cancer and its treat-
ment affect their lives, how this is managed in everyday 
life, how this changes with time and what influences this. 
HORIZONS will provide comprehensive data needed 
by patients, members of their social networks, clinical 
and policy communities to inform the transformation 
to personalised care for people living with and beyond 
cancer.
HORIZONS is underpinned by a conceptual frame-
work (see figure 1) informed by three areas of work:
1. Foster and Fenlon’s3 conceptual framework of recovery 
of health and well-being following cancer treatment 
hypothesises that health and well-being are positively 
associated with presence of support for the individual, 
their confidence to manage problems faced as a conse-
quence of their cancer and negatively associated with 
problems experienced such as fatigue and pain.15
2. Burden of treatment theory2 seeks to understand how 
people self-manage the demands placed on them by 
cancer, its treatment and the healthcare system, their 
capacity to do this work and individual/group mecha-
nisms that promote or inhibit development of capacity 
for self-management.
3. A social network analytical approach will enable us 
to explore self-management support in survivorship 
conceptualising personal networks as a source from 
which resources can be mobilised and used and the 
types of illness ‘work’ undertaken within peoples’ so-
cial networks which contribute to personal coping 
and management.16 17 A major source of support can 
come from personal networks. Social network mem-
bers are recognised as having an important role in 
self-management.16
The study is funded by Macmillan Cancer Support a 
UK charity that supports people living with and beyond 
cancer by providing information, support, services and 
funding research.
Figure 1 Conceptual framework underpinning the HORIZONS programme (informed by Foster and Fenlon,3 May et al,2 
Vassilev et al16 17)
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MEthods And AnAlysIs
A series of longitudinal cohorts will be established. Partic-
ipants will complete self-report questionnaires at regular 
intervals and clinical data will be collected. A nested 
qualitative study will be developed to understand, charac-
terise and explain how people connect with and mobilise 
supportive services and resources to help them to self-
manage the consequences of cancer and its treatment 
and to promote recovery of health and well-being. The 
study design will be developed during the first 2 years of 
the HORIZONS programme and submitted for ethical 
approval as an amendment to this protocol.
Activity will be structured around two linked research 
themes.
1. Recovery from cancer treatment: to explore determinants 
of recovery following primary cancer treatment. Our 
hypothesis is that curative cancer treatment disrupts 
health and well-being and people require time and 
support to recover. We will explore patterns of physi-
cal, psychological, social functioning and what helps 
or hinders this to characterise trajectories of recovery. 
We will also explore who is most at risk of a protracted 
or complex recovery pathway.
2. Self-managing the consequences of cancer: to examine how 
cancer and its consequences are managed and how 
management changes over time. Our hypothesis is 
that consequences of cancer and its treatment disrupt 
ways of managing, irrespective of level of health need, 
although those with complex needs will need most 
support. Those who feel supported to self-manage will 
be more able to self-manage. We will also determine 
the work involved in self-management, who is most 
likely to need support to self-manage, what helps/hin-
ders this, when support should be offered and in what 
form. It will also allow the identification of those who 
are least likely to self-manage successfully.
research questions
1. What impact does cancer diagnosis and treatment have 
on people’s lives in the short, medium and long term?
2. What are people’s health and well-being outcomes, 
experiences and self-management activities over time 
across different cancer types and what influences 
these?
3. How do people connect with and relate to others in 
mobilising resources that enable them to self-manage 
the consequences of cancer and treatment?
Patient and public involvement
Patient and public involvement (PPI) in HORIZONS 
began during the development of the study protocol 
and supporting documents. PPI representatives will 
contribute to the design of study outcome measures 
(questionnaires and case report forms (CRFs)) and other 
patient facing documentation including information 
sheets, invitation letters and patient newsletters. They will 
comment on recruitment methods, ways to improve study 
retention and the conduct of the qualitative study. The 
HORIZONS User Reference Group will meet regularly at 
the University of Southampton. PPI representatives will 
sit on the Strategic Advisory Board and Tumour Specific 
Expert Panels.
study setting
All patients meeting the eligibility criteria will be iden-
tified and recruited through their clinical teams prior 
to primary treatment. The study will be managed from 
the University of Southampton through the HORIZONS 
Coordinating Centre. HORIZONS has been adopted 
onto the NIHR CRN Portfolio. Participants will be iden-
tified and recruited from NHS treatment centres across 
the UK. Around 70 NHS Trusts and Health Boards will 
be selected covering a wide range of geographical loca-
tions across the UK, ethnically diverse populations and 
varying-sized hospitals.
Participants
Patients with the following cancers will be invited to 
participate: breast cancer diagnosed under age 50 years; 
non-Hodgkin’s lymphoma (NHL) (diffuse large B cell 
subtype: DLBCL); gynaecological cancers (endometrial, 
cervical, ovarian and vulval). Generic inclusion/exclusion 
criteria are below; see online supplementary appendix 1 
for specific requirements per cancer type.
The cohorts were chosen in collaboration 
with Macmillan Cancer Support’s Clinical Advisory Board. 
They were selected to allow exploration of a variety of 
treatment and recovery pathways and include people 
with less common cancers, under-researched groups and 
groups with particular survivorship concerns.
Inclusion criteria
1. New diagnosis of one of the selected cancer types de-
termined through clinical assessment, cytology, histol-
ogy or imaging or new/second primary cancer at a site 
previously treated for cancer.
2. Awaiting primary curative intent treatment, including 
neoadjuvant treatment.
3. ≥16 years old.
4. Able to complete questionnaires in English.
5. Able to provide written, informed consent.
Exclusion criteria
1. Disease recurrence/progression (either locally ad-
vanced or metastatic) at an existing cancer site.
2. Having treatment for a potentially curative recurrence 
of disease, for example, locally advanced disease (ie, 
they have been previously treated for the same cancer).
3. Metastatic disease from a cancer at another site (previ-
ous diagnosis of cancer at any other site would not be 
grounds for exclusion unless metastatic).
4. Synchronous primary cancers involving two or more of 
the HORIZONS specified cancer types.
Patients should be consented to HORIZONS prior 
to any treatment including surgery except for some 
ovarian and endometrial cancers where diagnosis is only 
confirmed at the time of surgery. These participants may 
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enter the study following confirmed diagnosis. If a partic-
ipant’s status (eg, staging) changes after confirmed diag-
nosis they will be reassessed for eligibility. If later found 
to be ineligible, participants will be informed of this by 
a member of their clinical team. Study participants who 
develop metastases/disease progresses after consent will 
remain in the study.
Assessment points
T0: baseline, following diagnosis and prior to initial cura-
tive intent treatment.
T1: 3 months after study entry to monitor early adapta-
tion, coping and detect initial treatment effects.
T2: 12 months after study entry to monitor later adapta-
tion, coping and detect initial treatment effects.
T3: 18 months after study entry to monitor further 
adaptation and early stages of recovery.
T4: 24 months after study entry to monitor conse-
quences in the longer term and how they are managed.
T5+: annual assessments to monitor consequences, 
emergence of late effects, comorbidities, lifestyle change 
and how they are experienced and managed across the 
life-course (subject to funding).
Measures
A selection of validated and study-specific outcome 
measures will be included, informed by the conceptual 
framework (figure 1), user and expert feedback. Key 
sociodemographic and socioeconomic information (eg, 
age, gender, ethincity, marital status, employment and so 
on) will be collected at baseline and characteristics that 
are likely to change will be included on a regular basis. 
Postcode data collected at consent will be used to calcu-
late a measure of relative area deprivation: the Index of 
Multiple Deprivation.18 A core set of measures will be 
administered to all participants at each assessment point. 
Additional measures and questions will be included at 
different time points including burden of treatment, 
comorbidities, life events, lifestyle, social networks 
and the use of health and social care services. Selected 
measures (eg, the SF-12v219) will be incorportated to 
enable comparisions with the UK Understanding Society 
longtudinal household panel survey that captures social, 
economic and health data on the UK general popula-
tion.20 All measures and questions assessed are described 
in supplementary appendix 2.
Core outcome measures
Quality of Life in Adult Cancer Survivors (QLACS)21 will be 
the primary outcome measure. QLACS21 was developed 
to assess QoL of adult cancer survivors measuring 12 
domains of cancer survivorship: generic (pain, fatigue, 
positive and negative feelings, cognitive and sexual prob-
lems, social avoidance) and cancer-specific (financial 
problems, family distress, recurrence distress, appearance 
concerns, benefits from cancer). QLACS has been vali-
dated among cancer survivors21 and has good convergent 
validity with other QoL measures (eg, Functional Assess-
ment of Cancer Therapy and Short Form 36).
EQ-5D-5L and the visual analogue scale22 23 assesses 
health status for clinical and economic appraisal. It 
comprises of five domains: mobility, self‐care, usual activ-
ities, pain/discomfort, anxiety/depression and five levels 
of severity. EQ-5D-5L has shown good measurement prop-
erties in a range of patient groups.24
EORTC-QLQ-C3025 examines the impact of cancer and 
its treatment with 30 items assessing function (physical, 
role, cognitive, emotional and social), symptoms (eg, 
fatigue, pain, and nausea and vomiting) as well as global 
health and QoL.
EORTC site-specific modules will be included to capture 
disease-specific consequences: high grade NHL (NHL-
HG2926), breast (BR2327), cervical (CX2428), endometrial 
(EN2429), ovarian (OV2830) and vulval cancers (VU3431). 
Site-specific modules will be supplemented with addi-
tional items from the EORTC item library32 to assess 
consequences not otherwise captured (eg, peripheral 
neuropathy, sexual function, menopausal symptoms).
Hospital Anxiety and Depression Scale (HADS)33 comprises 
of 14 items with two 7-item subscales assessing anxiety 
and depression symptoms. HADS is used across a range 
of settings demonstrating good internal consistency,34 
reliability and validity.35
Medical Outcomes Study Social Support Survey36 is a 19-item 
scale assessesing the level of social support available. It 
covers four domains (emotional/informational, tangible, 
affectionate support and positive social interaction) 
where higher scores indicate greater available support.
Self-efficacy for Managing Chronic Disease scale evaluates 
self-efficacy among pateints with chronic medical condi-
tions.37 At baseline, the original 6-item version of the scale 
will be used and from 3 months onwards, an additional 
five cancer-specific items will be included forming the 
Cancer Survivors’ Self-Efficacy Scale (CS-SES). The CS-SES 
has been demonstrated to have excellent reliability 
(Cronbach’s alpha 0.92).38
Medical details: clinical information including cancer 
type, stage, treatment details, comorbid conditions, 
recurrence, relapse, survival, genetic tests, family history, 
route to diagnosis, follow-up care, height and weight, will 
be abstracted from clinical records by the participating 
centre. Change in health condition and treatment will be 
monitored through self-report at follow-up and further 
collection of clinical data from participating centres at 
regular intervals.
sample size
Sample size calculations are based on the primary outcome 
measure. The mean generic summary score for QLACS is 
71.2 (SD 25.6).21 A difference of one half of a SD is often 
quoted as a minimum clinically important difference in 
sample size calculations: using 80% power to detect a 
difference of one half of a SD at the 0.05 significance level 
would require a minimum of 228 participants per cancer 
type, assuming unequal-sized groups will be compared in 
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the analyses. Assuming an intracluster correlation of 0.05 
to allow for similarities between participants from each 
participating centre and an average of 30 participants per 
participating centre the cluster correction increases this 
figure to 559 per cohort. Taking into account 10% with-
drawal and a range of 5-year survival rates according to 
cancer type and rounding up to allow for some subgroup 
analyses results in ~1000 participants per cohort. We are 
aiming for 3000 participants in total, although we antici-
pate around 750 DLBCL NHL patients. The sample size 
will be sufficient for other continuous measures, assuming 
the same size of difference (one half a SD). Subgroup 
analyses within cancer types will be possible, but numbers 
will be small for some instances, limiting the conclusions 
that can be drawn from these.
Pilot phase
During the pilot phase the HORIZONS Coordinating 
Centre will work with selected pilot participating centres 
to conduct feasibility work to assess study set up and 
training procedures, recruitment strategy, recruitment 
rates, representativeness of sample, appropriateness of 
measures for each of the tumour groups and clinical data. 
Pilot sites will be selected on the basis of geographical 
location, previous experience and hospital type.
Procedure
Patients will be identified at participating centres via a 
systematic screening process. Eligibility will be assessed 
using a standardised procedure and all eligible patients 
will be invited to participate over the recruitment period 
(September 2016 to March 2019). Eligible patients will, 
in general, be identified by a member of their direct 
care team through multidisciplinary team meetings or 
clinics. The HORIZONS Coordinating Centre will work 
with participating centres to review local procedures and 
determine best methods of screening and recruitment. 
Screening logs will be maintained at the participating 
centres. All eligible patients should be approached and 
invited to participate by a research nurse or member of 
the clinical team in the assessment clinic after their cancer 
diagnosis and before their first primary treatment. Partic-
ipation in other research studies is not an exclusion crite-
rion, unless it is an exclusion criterion of another study 
to which the participant is already consented. Patients 
who present as acute admissions (eg, emergency surgery) 
will be approached by their direct care team as soon as 
possible after surgery.
Participants will provide informed written consent to: 
participate (questionnaire completion and collection of 
medical details), be approached about related studies, 
for their data to be used in secondary data analyses and 
to be linked to UK national health databases. They will 
be given the opportunity to ask questions. They will then 
be given the baseline questionnaire to complete prior 
to their initial primary treatment which they will return 
directly to the HORIZONS Coordinating Centre along 
with their contact details form. Completed consent forms 
will be sent to the HORIZONS Coordinating Centre by 
participating sites. If participants require further time to 
consider participation, they may be given study informa-
tion to take home and return to the HORIZONS Coor-
dinating Centre. Research nurses at the participating 
centres may follow-up with a telephone call.
Follow-up questionnaires will be sent from the HORI-
ZONS Coordinating Centre following status checks. 
Patients will be given the option of completing these on 
paper or online.
Medical details CrF
CRFs will be completed by the clinical team at baseline, 
6 and 12 months and annually for all participants. Infor-
mation including cancer type, stage, treatment, comorbid 
conditions, recurrence and survival will be recorded. 
non-participation and withdrawal
Participants will remain free to withdraw from HORI-
ZONS at any time without giving a reason. Where 
possible reasons for non-participation will be recorded. If 
questionnaires have not been returned within 2 weeks, a 
reminder and duplicate questionnaire will be sent. If no 
response is received participants will not be approached 
again until the next follow-up questionnaire is due. 
Patients who decline any participation will be recorded 
on a decliners log containing aggregated data on age, 
gender, stage of disease and Eatern Cooperative Oncology 
Group (ECOG) performance status, in order to monitor 
the representativeness of HORIZONS. No identifiers of 
those who have declined will be held by the HORIZONS 
Coordinating Centre.
If, after consenting, a participant no longer meets the 
eligibility criteria they will be withdrawn from the study 
and their personal data and questionnaires destroyed. A 
member of the clinical team will inform the participant 
that they are no longer eligible for HORIZONS and will 
not be contacted again.
There are three withdrawal options:
1. No further contact: receive no further questionnaires 
but research team will retain and use information col-
lected previously and to continue to access their medi-
cal records for research purposes.
2. No further access: receive no further questionnaires, 
research team to have no further access to their med-
ical records, but information collected to date may be 
retained and used for research purposes.
3. No further use: receive no further questionnaires, re-
search team to have no further access to their med-
ical records and for information collected to date to 
be held only for regulatory purposes and not used for 
research purposes.
data quality
The HORIZONS Coordinating Centre will be respon-
sible for overseeing the handling and management of all 
study data. Paper copies of questionnaires and CRFs will 
be checked on receipt and any discrepancies or missing 
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data queried. For specific questionnaire time points, 
participants will be contacted by the HORIZONS Coordi-
nating Centre to complete missing items where possible 
to reduce missing data. Regular 10% data checks will be 
applied for data entry of paper questionnaires and CRFs 
into electronic databases. Electronic data will be routinely 
checked for accuracy.
Measures to minimise bias
At selection:
1. Patients identified through a systematic screening 
process.
2. Eligibility to participate assessed using a standardised 
procedure.
3. Non-identifiable data regarding reasons for non-par-
ticipation will be collected.
4. Non-identifiable sociodemographic data will be col-
lected (with verbal consent/agreement) on those who 
choose not to participate in the study.
5. Anonymised data collected for reasons why people 
were ‘missed’, that is, eligible but not invited to partic-
ipate (eg, due to logistical reasons).
Outcome measurement and analysis:
1. All outcomes are self-rated.
2. Strenuous efforts will be made to reduce missing data 
and maintain participants in HORIZONS, including 
status checks to ensure participants have not moved 
or died, reminders being mailed on non-response and 
telephone calls to capture missing data.
data protection, data storage and patient confidentiality
Data will be handled in compliance with Good Clinical 
Practice guidelines and data protection laws, following 
procedures laid out by the sponsor. This includes adher-
ence to University of Southampton privacy and data 
protection policies, European and National regulations. 
All data will remain confidential at all times. Online data 
are hosted by a UK company which takes appropriate 
safety and security measures. All document repositories 
and databases are secured by various means including, 
but not limited to, user access by special controlled user 
IDs and passwords.
data-sharing plans
Future data sharing will be subject to reasonable requests 
made in accordance with the Macmillan Survivorship 
Research Group (MSRG) data access policy. The MSRG 
data access policy and associated forms are available 
online at: https://www. horizons- hub. org. uk/ access_ data. 
html.
Analysis
Recovery from cancer treatment
Descriptive statistics will characterise the primary outcome 
of QoL (QLACS), describe health status (EQ-5D-5L) 
and symptoms/functioning (EORTC QLQ-C30 and 
site-specific modules). Changes in these outcomes over 
time will be investigated using longitudinal methods 
including generalised estimating equations. Group-based 
trajectory analyses will investigate whether there are 
distinct subgroups of recovery within each cohort. 
Factors that may influence recovery will be included in 
the regression models informed by the conceptual frame-
work. The varying contribution of these factors will be 
assessed to determine which have the most influence 
on the outcomes of QoL, health status, well-being and 
symptoms/functioning following treatment. Recurrence 
and survival (overall and disease-specific) will be anal-
ysed using standard methods of survival analysis, such as 
Kaplan-Meier analysis.
Self-managing the consequences of cancer
Descriptive statistics will summarise participants’ self-man-
agement activities, and their capacity and confidence 
to self-manage problems, and longitudinal analyses as 
previously described will assess changes over time in the 
measures of self-management (Health Education Impact 
Questionniare).39 Factors that may influence self-man-
agement will be investigated in the regression models 
informed by the conceptual framework. Analyses will 
explore how self-management practices relate to recovery 
of QoL, health and well-being. Self-management activ-
ities will be compared across groups including cancer 
and treatment types using statistical methods already 
described, and analyses such as group-based trajec-
tory analyses will investigate whether there are distinct 
subgroups with different healthcare needs.
Patterns of missing data will be investigated in the anal-
ysis. Quantitative data will be analysed using statistical 
packages such as SPSS version 25 and Stata version 15.
EthICs
Independent peer review of HORIZONS was coordinated 
by Macmillan Cancer Support in October 2013. HORI-
ZONS has ethical and research governance approvals 
(IRAS Project ID: 202342, REC reference number 16/
NW/0425) and is adopted onto the National Institute 
for Health Research Clinical Research Network portfolio. 
University Hospital Southampton Foundation Trust is the 
Sponsor and will provide NHS to NHS indemnity. Univer-
sity Staff will be covered by the University of Southamp-
ton's Professional Indemnity and Clinical Trials Insurance 
for the conduct of the research.
We do not anticipate that there will be any risks to 
participants, but participants will be advised that, if they 
have any concerns about their health as a result of study 
participation, to contact their general practitioner (GP) 
or hospital doctor or nurse. The HORIZONS Coordi-
nating Centre will provide details of support organisa-
tions. No individual response to questionnaire answers 
will be made by the HORIZONS Coordinating Centre, 
and participants will be made aware of this.
Protocol deviations will be documented and reported 
to the chief investigator (CI) and sponsor immediately. 
Steps will be taken to ensure questionnaires are sent 
out on time. Only serious adverse events (SAEs) during 
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study participation deemed to be due to participation in 
HORIZONS will be reported to the CI within 24 hours of 
the participating centre learning of its occurrence. Local 
investigators will report any related SAEs as required by 
their local Research and Development Office.
dIssEMInAtIon
We will engage with our Scientific Advisory Board, Tumour 
Specific Expert Panels, User Reference Group, Macmillan 
Cancer Support and the University of Southampton to 
ensure maximum publicity and benefit. Findings will be 
widely disseminated through Macmillan Cancer Support, 
high impact publications, conference presentations and 
stakeholder events. We will make recommendations on 
where to target services and resources for cancer survi-
vors. We will work with service users through our PPI 
events to disseminate study findings and discuss the prog-
ress of the study. HORIZONS has a dedicated website 
www. HORIZONS- hub. org. uk.
The full study dataset will be available to research staff 
within the HORIZONS Coordinating Centre. Other 
parties will only have access to the dataset, while the 
study is ongoing and the main results are being analysed 
and reported, where there are relevant agreements and 
permissions in place.
study MAnAgEMEnt
The study will be delivered by the HORIZONS Coordi-
nating Centre in the MSRG, University of Southampton, 
delegated this task by the sponsor. The study team is 
supported by a Programme Management Group (coappli-
cants), Strategic Advisory Board, User Reference Group, 
Tumour Specific Expert Panels and Data Monitoring 
Committee who are consulted and advise on various 
aspects of HORIZONS.
suMMAry
The aims of HORIZONS are to:
1. Establish a series of cohorts of cancer patients to cap-
ture their health-related outcomes and experiences 
from beginning active treatment and regularly over 
time.
2. Maintain and develop HORIZONS as an accessible 
resource to explore consequences of different cancer 
diagnoses and treatments from the individual perspec-
tive.
3. Inform policy and practice-based innovative solutions 
to minimise health burden and maximise support 
available to people diagnosed with cancer.
The HORIZONS evidence will:
1. Improve understanding of the consequences of differ-
ent cancers and treatments, the impacts of comorbidi-
ties, recurrence and late effects, the characteristics that 
lead to increased risk of poor recovery, the ability to 
self-manage and what helps or hinders this.
2. Support the transformation of personalised care for 
people living with and beyond cancer. Better informa-
tion on short-term, medium-term and long-term out-
comes and experiences across cancer types and treat-
ments will enable health professionals to provide more 
personalised care to their patients tailored to their 
needs and to support people to live as healthy and ac-
tive a life as possible.
3. Enable us to predict who is most likely to need sup-
port, what form this should take and when it should 
be available.
4. Help to prepare future patients for likely consequenc-
es and how long these might last following treatment 
so that they know what to look out for, when to seek 
support and to support decision-making where appro-
priate.
5. Identify areas for service innovation and other solu-
tions to support cancer survivors and their personal 
networks to manage the consequences of cancer and 
its treatment across all aspects of their lives.
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